DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Motzer R.
Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) vs. first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC).
In: J Clin Oncol 2013;
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.